Skip to main content
placeholder image

Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2010

Citation


  • Karapetis, C. S., Clingan, P. R., Leighl, N. B., Durbin-Johnson, B., O'Neill, V., & Spigel, D. R. (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7535. doi:10.1200/jco.2010.28.15_suppl.7535

Web Of Science Accession Number


Start Page


  • 7535

End Page


  • 7535

Volume


  • 28

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2010

Citation


  • Karapetis, C. S., Clingan, P. R., Leighl, N. B., Durbin-Johnson, B., O'Neill, V., & Spigel, D. R. (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7535. doi:10.1200/jco.2010.28.15_suppl.7535

Web Of Science Accession Number


Start Page


  • 7535

End Page


  • 7535

Volume


  • 28

Issue


  • 15_suppl

Place Of Publication